ERBB2 and breast carcinoma: Several HER2 inhibitors such as Trastuzumab, Pertuzumab, Lapatinib, Naratinib, and Trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer [28].